News
Kit Ng wins Best Research Poster at the Wyoming Medical Society conference.
October 25, 2024
Kit was selected as a winner of a Trainee Research Award and Best Abstract Award at the 2025 Western Medical Research Conference (January 16-18, 2025) in Carmel, California for his abstract resulting from his summer internship titled “Incidence and kinetics of bloodstream infections and cytokine release syndrome, and biomarkers to differentiate them after chimeric antigen receptor-modified-T-cell immunotherapy.” He also received a travel award and the best medical student poster at the Wyoming Medical Society Conference for the University of Wyoming WWAMI Medical School. Congratulations, Kit!
What Does It Mean to Be Immunocompromised?
New York Times | October 10, 2024
Dr. Hill speaks with Knvul Sheikh on what it means to be immunocompromised.
The ImmunOptmize Network receives funding support from the Washington Research Foundation
Washington Research Foundation | May 30, 2024
What is pemgarda, and Can it Prevent COVID-19?
Patient Power | May 20, 2024
COVID-19 prior to cellular therapy is likely not a cause for alarm
Fred Hutch Science Spotlight | April 17, 2024
In the crosshairs: herpesvirus 6B as a potential cause of idiopathic pneumonia
Fred Hutch Science Spotlight | February 21, 2024
Strong Evidence Linking HHV-6B To Pneumonia in Transplant Patients
HHV-6 Foundation | February 2024
Investigating CMV reactivation in CARTx patients reveals high risk patients
Fred Hutch Science Spotlight | December 18, 2023
When Should Allogeneic HCT Recipients Receive SARS-CoV-2 Vaccination?
MedPage Today | June 27, 2023
Dr. Joshua Hill speaks with MedPage today regarding Allogeneic HCT recipients and SARS-CoV-2 vaccination.
How blood cancer research might help organ transplant patients
Hutch News Stories | February 16, 2023
Fred Hutch News Service interviews Dr. Hill on the Hill Groups' recent work.
Vaccination after CAR-T-cell therapy
Science Spotlight | December 20, 2021
The December 2021 issue of Fred Hutch's Science Spotlight features a write-up regarding research conducted by Dr. Carla Walti, a Visiting Fellow in the Hill Group.
Cancer Patients May Have Double the Risk of Breakthrough Infection After COVID-19 Vaccination
Cancer Therapy Advisor | December 7, 2021
Dr. Josh Hill speaks with Cancer Therapy Advisor regarding COVID-19 breakthrough infection risks within vaccinated cancer patients.
IDSA Honors 199 Distinguished Clinicians, Scientists with FIDSA Designation
IDSA | November 16, 2021
Dr. Josh Hill is designtated as a Fellow of IDSA.
Remdesivir Averts Hospitalization in High-Risk COVID Patients
MedPage Today | November 2, 2021
Dr. Josh Hill discusses the phase III Remdesivir study results.
Early 3-Day Remdesivir Regimen Reduces COVID-19 Hospitalization, Death by 87%
ContagionLive | September 30, 2021
In an interview, Dr. Josh Hill discusses what the new data mean for using Remdesivir to reduce COVID-19 burden.
Remdesivir Averts Hospitalization in Study of High-Risk Patients
Bloomberg | September 22, 2021
Bloomberg interviews Dr. Josh Hill about research he is presenting at an upcoming late breaker IDWeek 2021 talk.
Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants
JAMA | May 5, 2021
Dr. Josh Hill is quoted in this article regarding immunocrompised patients.
The Center for International Blood and Marrow Transplant Research (CIBMTR) Launches Study of COVID-19 Vaccine Immunogenicity in Patients With Hematological Malignancies Who Have Received Cellular Therapy
businesswire | May 18, 2021
Dr. Josh Hill is the Study Chair for the joint CIBMRT and BMT CTN study.
'On-your-toes' approach to managing infection risk needed as CAR T-cell therapy evolves
Healio | March 17, 2021
In Practice interviews Dr. Josh Hill on infection risk during CAR T-cell therapy.
Masks and social distancing may still be needed for people with compromised immunity
King 5 News | May 14, 2021
King 5 News interviews Dr. Josh Hill on future masking and social distancing needs for people with compromised immunity.
2021 Fialkow Scholars Award
UW Department of Medicine | May 13, 2021
Dr. Joshua Hill is the recipient of the 2021 Fialkow Scholar Award.
Infection prevention in patients receiving CAR T-cells and Infectious complications after CAR T-cell therapy
The Video Journal of Hematological Oncology | February 10, 2021
VJHEMONC interviews Dr. Josh Hill during the 3rd European CAR T-cell Meeting.
How do I manage the risk of infection in patients treated with immunotherapies?
Multiple Myeloma Hub | February 18, 2021
Dr. Josh Hill speaks with the Multiple Myeloma Hub on managing infection risk in patients treated with immunotherapies.
What Cancer Patients Need to Know about COVID-19 Vaccines
SHARE | February 11, 2021
In this webinar, Dr. Josh Hill answers the most common vaccine related questions and explains the vaccine in relation to cancer patients and their treatment.
Are Coronavirus Vaccines Safe and Effective for People With Cancer?
Cancer Health | December 24, 2020
Dr. Josh Hill weighs in on vaccines in cancer patients during an American Society of Clinical Oncology (ASCO) expert panel.
CDC release revised guidance for quarantine length
Q13 FOX | December 2, 2020
Dr. Josh Hill responds to the recent recommendations from the CDC on new quarantine guidelines.
Cancer researchers cross over to COVID-19 clinical trials
Medscape | October 13, 2020
In a news story, Dr. Josh Hill discussed treating immune responses in COVID-19 patients.
Antiviral immunity survives CD19-directed therapy
Science Spotlight | January 2020
From the Hill and Turtle laboratories, Vaccine and Infections Disease Division and Clinical Research Division
$3.3M Cancer Moonshot grant to study CAR T-cell therapy and infection risk
Hutch News | Jake Siegel | January 2020
Dr. Josh Hill will study how immunotherapy impacts patients’ ability to fight off bugs.
Patients’ Humoral Immunity Is Preserved, With Low Rates of Viral Infections, After Anti-CD19 CAR T-Cell Therapy
ASH Clinical News | December 2019
The two commercially available chimeric antigen receptor (CAR) T-cell products both target cells expressing the CD19 antigen, which is present on malignant and nonmalignant B cells, introducing the possibility that a patient’s humoral immunity may be depleted after treatment. Little is known about the long-term effects of this treatment on patients’ immunity, but a new study provides reassurance that pathogen-specific antibodies and pre-existing humoral immunity are preserved in CAR T-cell–treated adults with B-cell malignancies. This immunity is preserved even in patients who had a complete response (CR) and B cell aplasia.
Patients with iciHHV-6 have higher inflammatory cytokines and develop acute graft vs host disease a week earlier
HHV-6 Foundation | December 2019
Joshua Hill, MD and colleagues from the Fred Hutchinson Cancer Research Center in Seattle found inherited chromosomally-integrated HHV-6 (iciHHV-6) to be associated with increased levels of inflammatory cytokines and an earlier onset of acute graft-versus-host disease (aGVDH) in transplant patients.
HHV-6B lung infection doubles the mortality rate of transplant patients with respiratory disease
HHV-6 Foundation | October 2019
Human herpesvirus 6B in lung fluid of bone marrow transplant recipients with pneumonia is associated with a 2-fold increased risk of death. Importantly, HHV-6B positive patients who were treated with an antiviral had a 60% lower risk of death.
Dr. Joshua Hill comments on changing cancer therapies
Hutch News | Sabin Russell | June 17, 2019
Infections in immune-compromised patients: 5 new frontiers.
Infectious disease experts gather in Seattle to find solutions for patients with compromised immunity.
A podcast and radio broadcast with Dr. Joshua Hill on his research into infection risk in cancer patients treated with CD19-targeted CAR-T therapy
The Onco’Zine Brief on PRX | Mar 3, 2018
In this interview, Dr. Hill discusses the promise and perils of CD19-targeted CAR-T cell therapy.
Dr. Joshua Hill receives Amy Strelzer Manasevit Research Program grant
Hutch News | Mary Engel | June 6, 2018
Award will help fund 'paradigm shift' in diagnosing post-transplant infections.
First systematic study of infections after CAR T-cell therapy
Hutch News | Susan Keown | Nov. 6, 2017
"Benchmark" research could help reduce complications of emerging immunotherapy
Dr. Joshua Hill wins the HHV-6 Foundation Caroline B. Hall Young Investigator Award
HHV-6 Foundation website | Jan. 15, 2016
Dr. Hill is recognized for his work on projects including the use of a reverse transcription PCR test to identify HHV-6 infections in pulmonary disease and pneumonia after transplantation.
Dr. Joshua Hill receives NIH career development award
HHV-6 Foundation website | June 30, 2015
The K23 grant from the National Institute of Allergy and Infectious Diseases will support Dr. Hill's committed efforts to advance understanding of diseases associated with HHV-6 in hematopoietic cell transplant recipients.
Interview with Michael Boeckh and Joshua Hill on potential risks for ciHHV6 patients undergoing HCT
HHV-6 Foundation website | Sep. 30, 2014
Drs. Boeckh and Hill discuss important considerations for treatment of transplant patients.
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.